ABT
$103.10-1.70%
as of close, Oct 27, 2026
☾ AH $103.10 -1.70%
ABT — Abbott Laboratories price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDE
40.050.060.070.080.090.0100.0110.0120.0130.0140.0050.0M100.0M$103.10—20162019202120242026
2026-10-27
Price$103.10
MA20$99.86
MA50$110.63
Vol35.3M
Key stats#
Price data
- Price
- $103.10
- YTD price return
- -17.71%
- YTD total return
- -15.67%
- Market cap
- 178.4B
- Enterprise value
- 207.3B
- Shares outstanding
- 1.7B
- 52W low
- $81.97
- 52W high
- $132.03
- From 52W high
- -21.91%
- From 52W low
- +25.78%
- 52W range
- 42%
- Beta
- 0.58
Volume
- Rel volume
- 0.65×
- 30D volume
- 10M
- 30D $ vol
- 1B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$46.9M
- Insider net 1Y
- −$42.9M
Form 4 transactions by trade date, as filed; latest on file 2026-09-02.
Fundamentals
- Sales (ttm)
- 46.6B
- Sales/share
- $26.92
- EPS (ttm)
- $3.11
- FCF (ttm)
- 7.8B
- FCF/share
- $4.52
- Book value/share
- $29.54
- Net margin
- 11.65%
- ROE
- 10.61%
- ROA
- 4.97%
- Debt / equity
- 0.58×
- Current ratio
- 1.38
Growth (CAGR, ttm) · 10Y
- Sales
- +8.07%+5.01%+2.98%+8.53%
- Net income
- -61.22%+1.68%-3.18%+9.07%
- FCF
- +15.49%+12.55%-1.97%+16.56%
- Shares
- -0.58%-0.10%-0.48%+1.64%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -61.19%+1.84%-2.69%+7.48%
- Sales/share
- +8.70%+5.11%+3.48%+6.77%
- FCF/share
- +16.17%+12.65%-1.50%+14.68%
- Book value/share
- +1.67%+11.30%+9.15%+7.70%
- Dividend/share
- +6.90%+7.87%+8.81%+9.38%
- Price
- -18.95%+3.55%-4.19%+9.94%
- Total return
- -16.93%+5.75%-2.26%+12.03%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 33.2×
- P/OI (ttm)
- 24.3×
- Fwd P/E
- 17.4×
- P/S (ttm)
- 3.8×
- P/B (mrq)
- 3.5×
- P/FCF (ttm)
- 22.8×
- EV/EBITDA (fy)
- 19.2×
- EV/Sales (ttm)
- 4.4×
- FCF yield (ttm)
- 4.39%
- Dividend yield (fwd)
- 2.44%
- Dividend yield (ttm)
- 2.44%
- Dividend/share (fwd)
- $2.52
- Buyback yield (realized, 1y)
- 0.58%
- Shareholder yield (realized, 1y)
- 2.38%
- Buyback yield (cash, ttm)
- 1.03%
- Shareholder yield (cash, ttm)
- 3.42%
Vs own 10Y history
- P/E
- 36th
- P/OI
- 19th
- P/S
- 19th
- P/B
- 18th
- P/FCF
- 13th
Bar = where today’s multiple sits in ABT’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
-1.70%
5D
+0.63%
1M
+1.79%
3M
-1.33%
YTD
-17.71%
1Y
-18.93%
5Y
-19.27%
Recent filings#
- Oct 21Earnings · Earnings release — EPS $1.42 vs $1.43 est. (−0.7%) 1.9%
- Sep 2Insider sale · MCCOY JOHN A. JR. (VICE PRESIDENT AND CONTROLLER) sold 27 shares for $2,958 at $109.54
- Aug 25Insider sale · Ford Robert B (CHAIRMAN AND CEO · Director) sold 398,832 shares for $46.2M at $115.57–$116.19
- Aug 11Insider sale · Morrone Louis H. (EXECUTIVE VICE PRESIDENT) sold 5,850 shares for $643K at $109.83
- Jul 16Earnings · Earnings release — EPS $1.31 vs $1.28 est. (+2.3%); revenue $12.59B (+13% y/y) 10.7%
Financial statements
Open full ABT financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
